Agelbert NOTE: interesting article on this new test WITH IMMINENT FDA approval that MAY avoid the cost (and risk from intestinal perforation) involved in a colonoscopy. I am not sure yet if that means EXAS is a buy but I'm watching it... Cologuard Will Dominate Its Addressable Market May. 19, 2014 10:59 AM ET | 54 comments | About: EXACT Sciences Corporation (EXAS)
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Summary•A recent expert interview with a gastroenterologist indicated that Cologuard has significant market potential.
•Up to 30% of FIT patients would not be suitable for Cologuard, due to the need for colonoscopies roughly every 3-5 years anyway.
•Outside of those patients, Cologuard will own its addressable market and be rapidly adopted by physicians.
•Eventual penetration into the 70% range of this market is reasonable, and even at $300/test, Exact Sciences is undervalued.
http://seekingalpha.com/article/2225513-cologuard-will-dominate-its-addressable-market